Pharming reports positive Phase II topline data for leniolisib in genetic primary immunodeficiencies beyond APDS
Pharming presented positive Phase II topline data for leniolisib in genetic primary immunodeficiencies with immune dysregulation at ESID 2026. Study showed clinical improvements across key signs of immune dysregulation, supporting use beyond APDS; treatment was generally well tolerated. All participants who finished th